Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...
Investors are ramping up AI-related M&A to secure cutting-edge capabilities and market-beating returns, but high valuations and open-source ...
TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...
Following the Food and Drug Administration’s approval of Lutathera and Pluvicto in 2018 and 2022, respectively, we predicted ...
Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...
The UK pharma industry has warned that declining access to new medicines in England – down 10% in recent years – will ...
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
HHS Assistant Secretary of Public Affairs Tom Corry unexpectedly stepped down on Feb. 28. In a brief post on X Monday morning ...
US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...
CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the fourth quarter and year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback